Visual function improvement in patients with macroprolactinomas treated with bromocriptine. uri icon

Overview

abstract

  • We studied eight patients who had visual field defects secondary to prolactin-secreting macroadenomas and who had improved visual function with bromocriptine treatment without surgery or radiation. We recommend bromocriptine as a primary treatment for prolactin-secreting macroadenomas. If therapy is effective, continued regular neuro-ophthalmologic, endocrine, and imaging studies are necessary, because treatment with bromocriptine must be continued indefinitely.

publication date

  • May 15, 1990

Research

keywords

  • Bromocriptine
  • Pituitary Neoplasms
  • Prolactinoma
  • Vision, Ocular

Identity

Scopus Document Identifier

  • 0025278852

Digital Object Identifier (DOI)

  • 10.1016/s0002-9394(14)70683-x

PubMed ID

  • 2333917

Additional Document Info

volume

  • 109

issue

  • 5